Deleted in liver cancer-1 (DLC1): An emerging metastasis suppressor gene

Nicholas C. Popescu, Steve Goodison

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


While significant progress continues to be made in the early detection and therapeutic management of primary tumors, the incidence of metastatic disease remains the major cause of mortality. Accordingly, the development of novel effective therapies that can ameliorate dissemination and secondary tumor growth are a clinical priority. The identification of genetic and functional alterations in cancer cells that affect factors implicated in the metastatic process is critical for designing preventive and therapeutic strategies. Evidence implicating the protein deleted in liver cancer-1 (DLC1), a Rho GTPase activator, in metastasis has accumulated to a point where DLC1 may be considered as a metastasis suppressor gene. This review presents evidence supporting an anti-metastatic role for DLC1 in several human cancers and discusses the mechanisms contributing to its inhibitory effects. In addition, promising opportunities for therapeutic interventions based on DLC1 function and downstream pathways involved in the metastatic process are considered.

Original languageEnglish (US)
Pages (from-to)293-302
Number of pages10
JournalMolecular Diagnosis and Therapy
Issue number3
StatePublished - Jun 2014

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology


Dive into the research topics of 'Deleted in liver cancer-1 (DLC1): An emerging metastasis suppressor gene'. Together they form a unique fingerprint.

Cite this